Mankind Pharma Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on August 07, 2025
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Mankind Pharma held its 34th AGM on August 7, 2025, via video conferencing, and all four resolutions were passed with the required majority. The resolutions included adoption of standalone and consolidated audited financial statements for FY ended March 31, 2025 (99.97% in favour), re-appointment of Mr. Sheetal Arora as a director retiring by rotation (99.68% in favour), appointment of M/s. Amit Gupta & Associates as Secretarial Auditors (99.84% in favour), and ratification of the Cost Auditor's remuneration for FY 2025-26 (99.9999% in favour). Of the 412,728,748 total shares, about 392.8 million were polled through e-voting. Promoters holding 299,960,612 shares (around 72.7% stake) voted entirely in favour of all resolutions. There were 173,580 shareholders on the record date of July 31, 2025, with 126 shareholders attending via video conferencing.
This is a routine regulatory filing confirming routine AGM approvals; all resolutions passed comfortably with strong promoter backing, so there is no negative signal for shareholders. The slight dissent (0.32%) on director re-appointment is minor and unlikely to affect the stock price.